Table 4.
Overview of selected neoadjuvant trials in MIBC testing immunotherapy combined with novel therapeutic agents.
| Novel agents-immunotherapy combinations | |||||
|---|---|---|---|---|---|
| Drugs | Number of patients | Study design | Primary endpoint | Status | Trial ID |
| Durvalumab + Olaparib | 29 | Phase II Open Label Sigle arm |
pCR rate | Completed | NCT03534492 (NEODURVARIB) |
| Atezolizumab + Cabozantinib | 42 | Phase II Open Label Sigle arm |
pRR rate | Not yet recruiting | NCT04289779 (ABATE) |
| Pembrolizumab + Epacadostat | 38 | Phase II Open Label Sigle arm |
pCR rate | Not yet recruiting | NCT03832673 |
ID, identification number; GC, gemcitabine, cisplatin; pCR, pathologic complete response; pRR, pathologic response rate.